Olpasiran Leads to Significant Reduction in Oxidized Phospholipids

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized phospholipids (OxPL) on apolipoprotein B (apoB), according to a study published online Feb. 12 in JAMA Cardiology.

Robert S. Rosenson, M.D., from Mount Sinai Hospital in New York City, and colleagues examined the effect of olpasiran on OxPL, high-sensitivity interleukin 6 (hs-IL-6), and high-sensitivity C-reactive protein (hsCRP) in a multicenter, phase 2, dose-finding randomized trial involving 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels >150 nmol/L. Participants were randomly assigned to receive one of four active subcutaneous doses of olpasiran versus placebo: 10 mg every 12 weeks (Q12W); 75 mg Q12W; 225 mg Q12W; or 225 mg every 24 weeks (Q24W).

The researchers found that the placebo-adjusted mean percentage change in OxPL on apoB (OxPL-apoB) concentration from baseline to week 36 was −51.6, −89.7, −92.3, and −93.7 percent for the 10-mg Q12W, 75-mg Q12W, 225-mg Q12W, and 225-mg Q24W doses, respectively, with maintenance of these effects observed to 48 weeks (−50.8, −100.2, −104.7, and −85.8 percent, respectively). For patients treated with olpasiran, there was a strong correlation between percentage reduction in Lp(a) and OxPL-apoB (r = 0.79). No significant impact was seen on hs-CRP or hs-IL-6 for olpasiran versus placebo to weeks 36 or 48.

"Olpasiran leads to a significant reduction in OxPL on apoB," the authors write. "It remains unknown whether these observed effects may offer incremental benefit beyond olpasiran's effect of Lp(a) lowering alone."

Several authors disclosed ties to pharmaceutical companies, including Amgen, which manufactures olpasiran and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords